"I am proud of what we have accomplished in 2019. Together, we successfully implemented our growth strategy to become a stronger partner for our customers. For our team, we continued to enhance our culture to be an even better place to work. For our shareholders, we delivered a solid financial performance, positioning our Company for an exciting future."
Alan HirzelOur purpose – to serve life scientists to help them achieve their mission, faster – drives everything we do.
By providing life scientists with critical biological tools and reagents needed for research, drug discovery and diagnostics, we are helping advance scientific discovery, resulting in better health outcomes and improving lives. We recognise that we succeed only because we help our customers achieve their goals, faster. We are committed to increasing and improving the ways in which we are able to support life scientists and achieving this in a way that benefits our shareholders and our other stakeholders.
As we continue to execute our strategy to deliver sustainable performance and growth, our culture will help drive success.
We will – continue to dedicate ourselves to our customers, anticipating and responding to their needs in order to deliver an exceptional experience; be audacious in our approach to innovation and in finding solutions to existing and new biological questions; and earn trust by delivering quality products and services with agility and speed, executing on our plans and, at all times, acting responsibly and with integrity.How Abcam’s scientists are helping the research community move closer to a cure for Parkinson’s disease.
How an audacious approach to innovation is helping advance research in rare disease areas with high unmet medical need.
How an agile approach to new product development is helping increase our knowledge of epigenetics.
Note:
Certain financial measures in this Annual Report and Accounts, including adjusted results above, are not defined under IFRS and are alternative performance measures as described on page 141. All adjusted measures are reconciled to the most directly comparable measure prepared in accordance with IFRS in note 7 to the consolidated financial statements
It is my pleasure to introduce Abcam’s 2019 Annual Report, which sets out the continued financial and strategic progress made by the company over the past 12 months, as well as our plans and priorities for the future.
Peter AllenAbcam has made good progress, both financially and strategically, over the past 12 months. We have continued to successfully implement our growth strategy whilst strengthening the organisation’s underlying capabilities to deliver further growth in the future.
The life science industry is vibrant, with increased research funding and capital investment supporting collaborative and global discovery networks.
Those research discovery networks – spanning genomics, epigenetics, proteomics and metabolomics – are converting physical biology into data at an unprecedented rate at a time when we are approaching unconstrained computing power. The insights from this data are not fully realised, and yet this progress is already producing rapid advances in scientific discovery and improving patient lives. Indeed, we expect the impact of the endeavours of researchers today to redefine how we will be treated in the future.
Chief Executive OfficerOur dedication to customer needs, team performance and our long-term investment perspective has helped Abcam to achieve sustained growth and expand its reach and influence over the last five years. Today, we are in a better position than ever before to pursue opportunities to continue to invest in, build and grow a successful global company.
Chief Financial OfficerThe Group delivered another solid financial performance in 2019, underpinning our continued investment in long-term growth
Our strategy is designed to increase growth and improve our long-term financial performance.
An overview of the strategic and operational milestones reached in 2018/19 and our future priorities are provided in the following tables:
2018/19 priorities
What we achieved
2018/19 priorities
What we achieved
2018/19 priorities
What we achieved
2018/19 priorities
What we achieved
2018/19 priorities
What we achieved
Corporate Responsibility
Behaving in a responsible and ethical way is central to the sustainable success of Abcam. We aspire to carry out our business activities to the highest ethical standards, act responsibly and make a positive impact in our interactions with all our stakeholders.